huahaipharm(SH:600521)2024-04-15 09:16Financial Performance - In 2023, the company achieved total revenue of 830,871.98 million yuan, a year-on-year increase of 0.52%[3] - The net profit attributable to shareholders was 82,621.68 million yuan, representing a decline of 29.25% compared to the previous year[3] - The net profit excluding non-recurring gains and losses was 89,846.90 million yuan, down 22.08% year-on-year[3] - The basic earnings per share decreased by 29.63% to 0.57 yuan[3] - The weighted average return on net assets fell by 5.96 percentage points to 10.59%[3] Assets and Equity - Total assets at the end of the reporting period were 1,859,825.20 million yuan, an increase of 2.46% from the beginning of the period[3] - Shareholders' equity attributable to the company increased by 6.92% to 806,882.19 million yuan[3] Business Challenges - The company faced challenges in the raw material drug business due to intensified competition and price declines[5] - The company reported a significant decrease in non-recurring gains and losses, primarily due to fair value losses from invested entities[5] Financial Reporting - The company warns that the financial data presented are preliminary and may differ from the final audited report[6]